218 related articles for article (PubMed ID: 23324534)
1. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Colliver JA; Ness JM; Ransohoff RM
J Neuroinflammation; 2013 Jan; 10():10. PubMed ID: 23324534
[TBL] [Abstract][Full Text] [Related]
2. Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Verhulst SJ; Ransohoff RM
Clin Exp Immunol; 2013 Jun; 172(3):427-36. PubMed ID: 23600831
[TBL] [Abstract][Full Text] [Related]
3. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
[TBL] [Abstract][Full Text] [Related]
4. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Hoefgen ER; Swan JA; Colliver JA
Cytokine; 2008 Oct; 44(1):26-32. PubMed ID: 18675552
[TBL] [Abstract][Full Text] [Related]
6. Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS.
Pranzatelli MR; McGee NR; Tate ED
J Neuroimmunol; 2018 Aug; 321():150-156. PubMed ID: 29685330
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study.
Pranzatelli MR; Allison TJ; Tate ED
Eur J Paediatr Neurol; 2018 Jul; 22(4):586-594. PubMed ID: 29555260
[TBL] [Abstract][Full Text] [Related]
8. Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders.
Pranzatelli MR; Tate ED; McGee NR; Colliver JA
J Neurol Sci; 2013 Mar; 326(1-2):53-8. PubMed ID: 23380454
[TBL] [Abstract][Full Text] [Related]
9. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED
Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis.
Piazza F; DiFrancesco JC; Fusco ML; Corti D; Pirovano L; Frigeni B; Mattavelli L; Andreoni S; Frigo M; Ferrarese C; Tredici G; Cavaletti G
J Neuroimmunol; 2010 Mar; 220(1-2):104-7. PubMed ID: 20149932
[TBL] [Abstract][Full Text] [Related]
12. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Ransohoff RM; Ness JM; Colliver JA
J Neuroimmunol; 2012 Feb; 243(1-2):81-8. PubMed ID: 22264765
[TBL] [Abstract][Full Text] [Related]
13. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED
Brain Dev; 2016 May; 38(5):439-48. PubMed ID: 26786246
[TBL] [Abstract][Full Text] [Related]
14. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS.
Pranzatelli MR; Tate ED; Travelstead AL; Verhulst SJ
Cytokine; 2011 Mar; 53(3):384-9. PubMed ID: 21211990
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, IVIg, and Tetracosactide (ACTH1-24) Combination Immunotherapy ("RITE-CI") for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations.
Pranzatelli MR; Tate ED; Alber M; Awadalla M; Blumkin L; Lina ES; Leiz S; Móser J
Neuropediatrics; 2018 Apr; 49(2):123-134. PubMed ID: 29258131
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus.
Hopia L; Thangarajh M; Khademi M; Laveskog A; Wallström E; Svenungsson E; Andersson M
Scand J Rheumatol; 2011; 40(5):363-72. PubMed ID: 21585290
[TBL] [Abstract][Full Text] [Related]
17. CCR4 agonists CCL22 and CCL17 are elevated in pediatric OMS sera: rapid and selective down-regulation of CCL22 by ACTH or corticosteroids.
Pranzatelli MR; Tate ED; McGee NR; Colliver JA; Ransohoff RM
J Clin Immunol; 2013 May; 33(4):817-25. PubMed ID: 23340773
[TBL] [Abstract][Full Text] [Related]
18. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms.
George-Chandy A; Trysberg E; Eriksson K
Arthritis Res Ther; 2008; 10(4):R97. PubMed ID: 18718031
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid biomarkers implicated in the pathogenesis of anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis.
Ikeda J; Shimojima Y; Usami Y; Ueno KI; Kishida D; Sekijima Y
Clin Rheumatol; 2020 Jun; 39(6):1803-1811. PubMed ID: 32036585
[TBL] [Abstract][Full Text] [Related]
20. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
